Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction

• Main Authors: Joseph J. Janicki, Michael B. Chancellor, Jonathan Kaufman, Michele A. Gruber, David D. Chancellor
• Format: Article
• Language: English
• Published: MDPI AG 2016-03-01
• Series: Toxins
• Subjects: liposome; bladder; interstitial cystitis; overactive bladder; botulinum toxin
• Online Access: http://www.mdpi.com/2072-6651/8/3/81

Bladder drug delivery via catheter instillation is a widely used treatment for recurrence of superficial bladder cancer. Intravesical instillation of liposomal botulinum toxin has recently shown promise in the treatment of overactive bladder and interstitial cystitis/bladder pain syndrome, and studies of liposomal tacrolimus instillations show promise in the treatment of hemorrhagic cystitis. Liposomes are lipid vesicles composed of phospholipid bilayers surrounding an aqueous core that can encapsulate hydrophilic and hydrophobic drug molecules to be delivered to cells via endocytosis. This review will present new developments on instillations of liposomes and liposome-encapsulated drugs into the urinary bladder for treating lower urinary tract dysfunction.